ONO-1301, a sustained-release prostacyclin analog, ameliorates the renal alterations in a mouse type 2 diabetes model possibly through its protective effects on mesangial cells

Hiroyuki Watatani, Hiroko Yamasaki, Yohei Maeshima, Tatsuyo Nasu, Norikazu Hinamoto, Haruyo Ujike, Hitoshi Sugiyama, Yoshiki Sakai, Katsuyuki Tanabe, Hirofumi Makino

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Diabetic nephropathy is the most common pathological disorder predisposing patients to end-stage renal disease. Considering the increasing prevalence of type 2 diabetes mellitus worldwide, novel therapeutic approaches are urgently needed. ONO-1301 is a novel sustained-release prostacyclin analog that inhibits thromboxane A2 synthase. Here we examined the therapeutic effects of the intermittent administration of slow-release ONO-1301 (SR-ONO) on diabetic nephropathy in obese type 2 diabetes mice, as well as its direct effects on mesangial cells. The subcutaneous injection of SR-ONO (3mg/kg) every 3 wks did not affect the obesity or hyperglycemia in the db/db obese mice used as a model of type 2 diabetes, but it significantly ameliorated their albuminuria, glomerular hypertrophy, glomerular accumulation of type IV collagen, and monocyte/macrophage infiltration, and also the increase of TGF-β1, α-smooth muscle actin (α-SMA) and MCP-1 compared to vehicle treatment. In cultured mouse mesangial cells, ONO-1301 concentration-dependently suppressed the increases in TGF-β, type IV collagen, α-SMA, MCP-1 and fibronectin induced by high ambient glucose, at least partly through prostacyclin (PGI2) receptor-mediated signaling. Taken together, these results suggest the potential therapeutic efficacy of the intermittent administration of SR-ONO against type 2 diabetic nephropathy, possibly through protective effects on mesangial cells.

Original languageEnglish
Pages (from-to)1-15
Number of pages15
JournalActa Medica Okayama
Volume69
Issue number1
Publication statusPublished - 2015

Fingerprint

Mesangial Cells
Epoprostenol
Medical problems
Type 2 Diabetes Mellitus
Kidney
Diabetic Nephropathies
Epoprostenol Receptors
Collagen Type IV
Obese Mice
Thromboxane A2
Albuminuria
Macrophages
Therapeutic Uses
Subcutaneous Injections
Fibronectins
Infiltration
Hyperglycemia
Hypertrophy
Chronic Kidney Failure
Smooth Muscle

Keywords

  • Diabetes mellitus
  • Diabetic nephropathy
  • ONO-1301
  • Prostacyclin
  • TGF-β1

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

ONO-1301, a sustained-release prostacyclin analog, ameliorates the renal alterations in a mouse type 2 diabetes model possibly through its protective effects on mesangial cells. / Watatani, Hiroyuki; Yamasaki, Hiroko; Maeshima, Yohei; Nasu, Tatsuyo; Hinamoto, Norikazu; Ujike, Haruyo; Sugiyama, Hitoshi; Sakai, Yoshiki; Tanabe, Katsuyuki; Makino, Hirofumi.

In: Acta Medica Okayama, Vol. 69, No. 1, 2015, p. 1-15.

Research output: Contribution to journalArticle

@article{f9fbc6151c57473980e22da5b9adf065,
title = "ONO-1301, a sustained-release prostacyclin analog, ameliorates the renal alterations in a mouse type 2 diabetes model possibly through its protective effects on mesangial cells",
abstract = "Diabetic nephropathy is the most common pathological disorder predisposing patients to end-stage renal disease. Considering the increasing prevalence of type 2 diabetes mellitus worldwide, novel therapeutic approaches are urgently needed. ONO-1301 is a novel sustained-release prostacyclin analog that inhibits thromboxane A2 synthase. Here we examined the therapeutic effects of the intermittent administration of slow-release ONO-1301 (SR-ONO) on diabetic nephropathy in obese type 2 diabetes mice, as well as its direct effects on mesangial cells. The subcutaneous injection of SR-ONO (3mg/kg) every 3 wks did not affect the obesity or hyperglycemia in the db/db obese mice used as a model of type 2 diabetes, but it significantly ameliorated their albuminuria, glomerular hypertrophy, glomerular accumulation of type IV collagen, and monocyte/macrophage infiltration, and also the increase of TGF-β1, α-smooth muscle actin (α-SMA) and MCP-1 compared to vehicle treatment. In cultured mouse mesangial cells, ONO-1301 concentration-dependently suppressed the increases in TGF-β, type IV collagen, α-SMA, MCP-1 and fibronectin induced by high ambient glucose, at least partly through prostacyclin (PGI2) receptor-mediated signaling. Taken together, these results suggest the potential therapeutic efficacy of the intermittent administration of SR-ONO against type 2 diabetic nephropathy, possibly through protective effects on mesangial cells.",
keywords = "Diabetes mellitus, Diabetic nephropathy, ONO-1301, Prostacyclin, TGF-β1",
author = "Hiroyuki Watatani and Hiroko Yamasaki and Yohei Maeshima and Tatsuyo Nasu and Norikazu Hinamoto and Haruyo Ujike and Hitoshi Sugiyama and Yoshiki Sakai and Katsuyuki Tanabe and Hirofumi Makino",
year = "2015",
language = "English",
volume = "69",
pages = "1--15",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "1",

}

TY - JOUR

T1 - ONO-1301, a sustained-release prostacyclin analog, ameliorates the renal alterations in a mouse type 2 diabetes model possibly through its protective effects on mesangial cells

AU - Watatani, Hiroyuki

AU - Yamasaki, Hiroko

AU - Maeshima, Yohei

AU - Nasu, Tatsuyo

AU - Hinamoto, Norikazu

AU - Ujike, Haruyo

AU - Sugiyama, Hitoshi

AU - Sakai, Yoshiki

AU - Tanabe, Katsuyuki

AU - Makino, Hirofumi

PY - 2015

Y1 - 2015

N2 - Diabetic nephropathy is the most common pathological disorder predisposing patients to end-stage renal disease. Considering the increasing prevalence of type 2 diabetes mellitus worldwide, novel therapeutic approaches are urgently needed. ONO-1301 is a novel sustained-release prostacyclin analog that inhibits thromboxane A2 synthase. Here we examined the therapeutic effects of the intermittent administration of slow-release ONO-1301 (SR-ONO) on diabetic nephropathy in obese type 2 diabetes mice, as well as its direct effects on mesangial cells. The subcutaneous injection of SR-ONO (3mg/kg) every 3 wks did not affect the obesity or hyperglycemia in the db/db obese mice used as a model of type 2 diabetes, but it significantly ameliorated their albuminuria, glomerular hypertrophy, glomerular accumulation of type IV collagen, and monocyte/macrophage infiltration, and also the increase of TGF-β1, α-smooth muscle actin (α-SMA) and MCP-1 compared to vehicle treatment. In cultured mouse mesangial cells, ONO-1301 concentration-dependently suppressed the increases in TGF-β, type IV collagen, α-SMA, MCP-1 and fibronectin induced by high ambient glucose, at least partly through prostacyclin (PGI2) receptor-mediated signaling. Taken together, these results suggest the potential therapeutic efficacy of the intermittent administration of SR-ONO against type 2 diabetic nephropathy, possibly through protective effects on mesangial cells.

AB - Diabetic nephropathy is the most common pathological disorder predisposing patients to end-stage renal disease. Considering the increasing prevalence of type 2 diabetes mellitus worldwide, novel therapeutic approaches are urgently needed. ONO-1301 is a novel sustained-release prostacyclin analog that inhibits thromboxane A2 synthase. Here we examined the therapeutic effects of the intermittent administration of slow-release ONO-1301 (SR-ONO) on diabetic nephropathy in obese type 2 diabetes mice, as well as its direct effects on mesangial cells. The subcutaneous injection of SR-ONO (3mg/kg) every 3 wks did not affect the obesity or hyperglycemia in the db/db obese mice used as a model of type 2 diabetes, but it significantly ameliorated their albuminuria, glomerular hypertrophy, glomerular accumulation of type IV collagen, and monocyte/macrophage infiltration, and also the increase of TGF-β1, α-smooth muscle actin (α-SMA) and MCP-1 compared to vehicle treatment. In cultured mouse mesangial cells, ONO-1301 concentration-dependently suppressed the increases in TGF-β, type IV collagen, α-SMA, MCP-1 and fibronectin induced by high ambient glucose, at least partly through prostacyclin (PGI2) receptor-mediated signaling. Taken together, these results suggest the potential therapeutic efficacy of the intermittent administration of SR-ONO against type 2 diabetic nephropathy, possibly through protective effects on mesangial cells.

KW - Diabetes mellitus

KW - Diabetic nephropathy

KW - ONO-1301

KW - Prostacyclin

KW - TGF-β1

UR - http://www.scopus.com/inward/record.url?scp=84923502543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923502543&partnerID=8YFLogxK

M3 - Article

C2 - 25703166

AN - SCOPUS:84923502543

VL - 69

SP - 1

EP - 15

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 1

ER -